FIELD: medicine, pharmaceutics.
SUBSTANCE: presented inventions refers to biotechnology, and particularly to oncology and concerns an oncolytic adenovirus, using it and a pharmaceutical composition containing this adenovirus. The characterized adenovirus contains a sequence intervening into its genome and coding hyaluronidase. The enzyme expression is controlled by a promoter active in animal's cells. The presented adenovirus can be used for preparing an agent for treating cancer and pre-cancer.
EFFECT: invention enables providing higher effectiveness and selectiveness of the therapy.
20 cl, 11 dwg, 10 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ADENOVIRUS CONTAINING ALBUMIN-BINDING SITE | 2015 |
|
RU2711371C2 |
| THERAPEUTIC COMPOSITIONS AND METHODS OF USING FOR TREATING CANCER | 2016 |
|
RU2720984C2 |
| RECOMBINANT ONCOLYTIC VIRUS, METHOD FOR ITS PRODUCTION, ITS APPLICATION AND THE DRUG ON ITS BASIS | 2020 |
|
RU2795230C1 |
| EXTENDED ADOPTIVE CELL THERAPY | 2014 |
|
RU2703438C2 |
| ONCOLYTIC ADENOVIRUSES ENCODING BISPECIFIC ANTIBODIES, AS WELL AS METHODS AND APPLICATIONS ASSOCIATED THEREWITH | 2016 |
|
RU2725799C2 |
| ADENOVIRAL VECTORS AND RELATED METHODS AND APPLICATIONS | 2009 |
|
RU2520823C2 |
| DESIGNING OF CARCINOLYTIC ADENOVIRUS RECOMBINANT, SPECIFICALLY EXPRESSING IMMUNOMODULATORY FACTOR GM-CSF IN TUMORAL CELLS AND ITS APPLICATION | 2004 |
|
RU2361611C2 |
| ONCOLYTIC VIRUS FOR IMMUNOLOGIC CONTROL POINT MODULATORS EXPRESSION | 2015 |
|
RU2696312C2 |
| MODIFIED ONCOLYTIC ADENO VIRUSES | 2019 |
|
RU2788638C2 |
| NEW MEDICAL AGENTS AND USE THEREOF | 2015 |
|
RU2739073C2 |
